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Sepsis claims an estimated 30 million episodes and 6 million deaths
per year, and treatment options are rather limited. Human
neutrophil peptides 1–3 (HNP1–3) are the most abundant neutro-
phil granule proteins but their neutrophil content varies because
of unusually extensive gene copy number polymorphism. A ge-
netic association study found that increased copy number of the
HNP-encoding gene DEFA1/DEFA3 is a risk factor for organ dys-
function during sepsis development. However, direct experimen-
tal evidence demonstrating that these risk alleles are pathogenic
for sepsis is lacking because the genes are present only in some
primates and humans. Here, we generate DEFA1/DEFA3 transgenic
mice with neutrophil-specific expression of the peptides. We show
that mice with high copy number of DEFA1/DEFA3 genes have
more severe sepsis-related vital organ damage and mortality than
mice with low copy number of DEFA1/DEFA3 or wild-type mice,
resulting from more severe endothelial barrier dysfunction and
endothelial cell pyroptosis after sepsis challenge. Mechanistically,
HNP-1 induces endothelial cell pyroptosis via P2X7 receptor-mediating
canonical caspase-1 activation in a NLRP3 inflammasome-dependent
manner. Based on these findings, we engineered a monoclonal anti-
body against HNP-1 to block the interaction with P2X7 and found
that the blocking antibody protected mice carrying high copy
number of DEFA1/DEFA3 from lethal sepsis. We thus demonstrate
that DEFA1/DEFA3 copy number variation strongly modulates sepsis
development in vivo and explore a paradigm for the precision treat-
ment of sepsis tailored by individual genetic information.
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Sepsis is defined as a life-threatening organ dysfunction that iscaused by a dysregulated host response to infection (1). It is a
common disease state that occurs in many clinical contexts. De-
spite advances in intensive care management and goal-directed
intervention, sepsis remains the leading cause of death among
critically ill patients worldwide (2). Currently, there are no ap-
proved treatment options for sepsis because of an incomplete
understanding of the key mechanisms regulating the host response
to sepsis and its progression into organ dysfunction, in addition to
the multifactorial nature of sepsis etiologies. Sepsis clearly imposes
a substantial global burden of morbidity and mortality (3–5).
One of the most important pathophysiologic hallmarks in sepsis is
the loss of the endothelial barrier function (6, 7). The endothelium
is the largest organ in the body, composed of a highly dynamic cell
layer that lines the interior surface of all blood vessels. The endo-
thelium orchestrates a multitude of physiological functions, in-
cluding the control of vascular tone, the movement of cells and
nutrients, the maintenance of blood fluidity, and the growth of new
vessels (8, 9). Loss of endothelial barrier function leads to the
dysregulation of hemostasis and vascular reactivity, as well as tissue
edema. Endothelial damage plays a central role in the progression
to organ failure during sepsis and is a major contributor to sepsis
mortality (10–12). More importantly, preserving endothelial barrier
function has been shown to improve the outcome of sepsis (13–15).
The mechanisms causing the quiescent endothelium to develop
barrier dysfunction during sepsis might hold the key to future
therapeutic strategies, but they are still largely unknown.
Defensins are short cationic, amphiphilic, cysteine-rich anti-
microbial peptides with three or four intramolecular disulfide
bonds. They are classified as α-, β-, and θ-defensins, of which the
first two are the most common human antimicrobial peptides
(16). The α-defensins, human neutrophil peptides (HNPs) 1–3,
are constitutively expressed in neutrophils and are the most
abundant neutrophil granule proteins. HNP1–3 differ in se-
quence in only the N-terminal amino acid, which is alanine for
HNP-1 and aspartate for HNP-3. This amino acid is missing in
HNP-2 peptide, and HNP-2 is thought to be a proteolytic
product of HNP-1 and HNP-3 (16, 17). In addition to their broad
repertoire of antimicrobial activities (18, 19), HNP1–3 exert
multiple immunomodulatory effects (20–22), as well as early
release alarmin activity to initiate the host response upon mi-
crobial invasion or tissue injury/damage (23). Studies in patients
have documented that the levels of HNP1–3 in various body
fluids (e.g., blood, bronchoalveolar lavage fluid, and sputum) are
greatly increased during sepsis (24). Furthermore, our previous
genetic association study found that the doses of genes encoding
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HNP1–3 (DEFA1/DEFA3), which display extensive copy number
variations (CNVs) (25, 26), significantly impacted the clinical
phenotype of sepsis, so that Chinese Han patients with high
genetic copy number of DEFA1/DEFA3 were more susceptible
to severe sepsis (defined as sepsis plus organ dysfunction
according to the old criteria for defining sepsis) (27). This as-
sociation is not unique because CNVs have been suggested to
play important roles in other complex diseases (28–30). How-
ever, despite the implication of HNP1–3 in sepsis outcomes, little
is known about the functional role of DEFA1/DEFA3 variants in
the pathophysiology of sepsis. Experiments to analyze the spe-
cific roles of DEFA1/DEFA3 CNVs in sepsis are challenging
because mice naturally lack neutrophil defensins (16). Thus, we
employed transgenic mice expressing HNP1–3 to explore the
nonredundant functions of DEFA1/DEFA3 genes in sepsis.
Here, we present experimental evidence for the impact of
DEFA1/DEFA3 CNVs on sepsis development and explore the
mechanism by which HNP1–3 promotes endothelial barrier
dysfunction and endothelial cell pyroptosis. We propose that
functional blockade of HNP1–3 in a genetically tailored manner
is rational strategy for development as a treatment for sepsis.
Results
Increased DEFA1/DEFA3 Gene Dose Worsens Outcomes in Sepsis. To
investigate the potential role of genetic CNVs of DEFA1/DEFA3
in sepsis development in vivo, we constructed a transgenic mouse
model that expresses human DEFA1/DEFA3 under its endoge-
nous regulatory sequences to recapitulate human defensin patho-
physiology. The mice were generated through microinjection of a
P1 artificial chromosome construct (clone P1 34), including the
human DEFA1/DEFA3 genes into fertilized oocytes of C57BL/6
mice, and two independent DEFA1/DEFA3 founder lines were
obtained. The two founder lines carry 6 copies and 48 copies of
DEFA1/DEFA3 genes, and the transgenes have integrated into
chromosome 5qF and chromosome 6qF3, respectively. The trans-
genic mice were viable and had normal growth, fertility, and lifespan.
Immunohistochemical analysis confirmed the expression of the
DEFA1/DEFA3 genes in the bone marrow (BM) myeloid cells of
transgenic mice and a cell-specific expression pattern of the DEFA1/
DEFA3 genes in peripheral blood neutrophils, but not in monocytes
and lymphocytes or in other perfused peripheral organs/tissues (SI
Appendix, Fig. S1A). Western blot analysis confirmed that BM mye-
loid cells of mice carrying more copies of DEFA1/DEFA3 genes had
much higher HNP protein levels than those of mice with lower copy
number (SI Appendix, Fig. S1B). The two transgenic lines are
referred to as mice with low copy numbers (LCN) and high copy
numbers (HCN) of DEFA1/DEFA3 genes, respectively, and are
compared with WT mice for potential biological differences.
To study the impact of genetically increased DEFA1/DEFA3
copy numbers on the development of sepsis, the transgenic mice
and WT mice were subjected to sublethal cecal ligation and
puncture (CLP), a commonly used sepsis model (31), and were
monitored for survival and pathophysiological changes. Inter-
estingly, 75% of the mice carrying HCN of DEFA1/DEFA3 genes
(9 of 12) died within 7 d after CLP, whereas only 15% of the
mice with LCN of DEFA1/DEFA3 genes (2 of 13) and 12% of
the WT mice (3 of 25) died over the 7-d study period (Fig. 1A).
Moreover, histopathologic analysis of lung (Fig. 1B and SI Ap-
pendix, Fig. S2A), liver (Fig. 1C and SI Appendix, Fig. S2B), and
kidney (Fig. 1D and SI Appendix, Fig. S2C) revealed that, com-
pared with the other two groups, the mice carrying HCN of
DEFA1/DEFA3 genes showed more severe organ injury, especially
at 72 h after CLP. These data suggest that increased dosage of
DEFA1/DEFA3 genes in mice leads to a poor outcome of sepsis.
Fig. 1. Increased gene copy number of DEFA1/DEFA3 aggravates sepsis development. (A) Survival over time after performance of CLP in WT mice (n = 25),
mice with a LCN of DEFA1/DEFA3 (n = 13), and mice with a HCN of DEFA1/DEFA3 (n = 12). Sham-operated mice were included as controls (n = 10 for each
group). **P = 0.002, ***P < 0.001, log-rank test. (B) Quantification of the lung injury score based on H&E-stained lung sections of WT mice, mice with LCN of
DEFA1/DEFA3, and mice with HCN of DEFA1/DEFA3 at 72 h after CLP or sham operation. **P = 0.003, ***P < 0.001, two-way ANOVA with Bonferroni
posttests. (C) Quantification of the liver injury score based on H&E-stained liver sections of WT mice, mice with LCN of DEFA1/DEFA3, and mice with HCN of
DEFA1/DEFA3 at 72 h after CLP or sham operation. ***P < 0.001, two-way ANOVA with Bonferroni posttests. (D) Quantification of the kidney injury score based on
H&E-stained kidney sections of WT mice, mice with LCN of DEFA1/DEFA3, and mice with HCN of DEFA1/DEFA3 at 72 h after CLP or sham operation. **P = 0.002,
***P < 0.001, two-way ANOVAwith Bonferroni posttests. (E) Survival over time of lethally irradiatedWTmice that were reconstituted with BM fromWTmice (n = 12),
mice with LCN of DEFA1/DEFA3 (n = 13), and mice with HCN of DEFA1/DEFA3 (n = 12) and that were subsequently subjected to CLP. *P = 0.016, **P = 0.006, log-rank
test. (F) Survival over time after intraperitoneal infection of WT mice (n = 18), mice with LCN of DEFA1/DEFA3 (n = 17), and mice with HCN of DEFA1/DEFA3 (n = 18)
with E. coli (4 × 106 colony forming units per mouse) prepared in 200 μL of PBS. Mice intraperitoneally injected with 200 μL of PBS were included as controls (n = 10 for
each group). **P = 0.004 betweenWTmice and mice with HCN of DEFA1/DEFA3, **P = 0.008 between mice with LCN of DEFA1/DEFA3 and mice with HCN of DEFA1/
DEFA3, log-rank test. In B–D, data are presented as dot plots with horizontal bars representingmeans ± SEM; n = 6 for each CLP group, and n = 5 for each sham group.
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To confirm the contribution of cell-specific expression of
the transgenes to the observed effect on sepsis, we generated
BM-chimeric mice by reconstituting lethally irradiated WT
mice with syngeneic BM with LCN of DEFA1/DEFA3, HCN
of DEFA1/DEFA3, or WT. Notably, the chimeric mice re-
ceiving BM with HCN of DEFA1/DEFA3 phenocopied the
original transgenic mice with HCN of DEFA1/DEFA3. After
induction of sepsis using sublethal CLP, HCN mice showed a
significantly reduced survival rate compared with the other
two groups (Fig. 1E).
To test the effect of increased dosage of DEFA1/DEFA3 genes
in another clinically relevant murine model of sepsis, we used
intraperitoneal administration of Escherichia coli. Again, mice
carrying HCN of DEFA1/DEFA3 had a significantly higher
mortality than mice with LCN of DEFA1/DEFA3 and WT mice
(Fig. 1F).
Thus, using the DEFA1/DEFA3 transgenic mouse models,
these findings suggest a causative link between DEFA1/DEFA3
CNVs and sepsis outcome.
Increased DEFA1/DEFA3 Gene Dosage Leads to Endothelial Barrier
Dysfunction During Sepsis. Sepsis is a frequently fatal condition
characterized by an uncontrolled and harmful host reaction to
microbial infection (3, 4). HNP1–3 have multiple biological
functions in host defense and inflammation, including antimi-
crobial action and the regulation of proinflammatory cytokine
production (16, 17, 20). Therefore, we questioned whether in-
creased DEFA1/DEFA3 gene dosage could affect the host in-
flammatory response and bacterial clearance during sepsis.
However, after sepsis onset, there were no significant differences
among the three studied groups in bacterial burden in the peri-
toneal cavity and peripheral blood (SI Appendix, Fig. S3 A and B)
or in plasma levels of inflammatory mediators TNF-α, IL-1β,
Fig. 2. Increased gene copy number of DEFA1/DEFA3 exacerbates leukocyte adhesion following sepsis. (A) Representative in vivo time-lapse imaging by two-
photon laser scanning microscopy showing leukocyte adhesion in mesenteric vessels in WT mice, mice with LCN of DEFA1/DEFA3, and mice with HCN of
DEFA1/DEFA3 at 72 h after CLP. Images are individual frames from a continuous time-lapse movie. Times are presented in seconds. In each group, the first
panel shows baseline adhesion in the vessel, the second and third panels show leukocyte adhesion at 3 s and 60 s after the baseline imaging, and the fourth
panel shows the merged images. Red indicates leukocyte adhesion at baseline; green indicates leukocyte adhesion at 3 s after baseline; blue indicates
leukocyte adhesion at 60 s after the baseline; yellow dashed lines indicate the vessel. (Scale bars, 50 μm.) (B) Quantitative measurements of firmly adhering
leukocytes in WT mice, mice with LCN of DEFA1/DEFA3, and mice with HCN of DEFA1/DEFA3 at 72 h after CLP. Firmly adherent leukocytes from at least three
fields-of-view per mouse were counted as the number of cells per square millimeter of vascular surface area. **P = 0.002 between WT mice and mice with
HCN of DEFA1/DEFA3, **P = 0.007 between mice with LCN of DEFA1/DEFA3 and mice with HCN of DEFA1/DEFA3, one-way ANOVA with Bonferroni posttests.
(C) Quantitative measurements of leukocyte rolling velocities in WT mice, mice with LCN of DEFA1/DEFA3, and mice with HCN of DEFA1/DEFA3 at 72 h after
CLP. *P = 0.048, **P = 0.005, one-way ANOVA with Bonferroni posttests. In B and C, n = 7 for WT mice with CLP and mice carrying HCN of DEFA1/DEFA3 with
CLP, n = 9 for mice carrying LCN of DEFA1/DEFA3 with CLP.
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IL-6, IL-10, IFN-γ, and IL-17A, as well as KC and MCP-1 (SI Ap-
pendix, Fig. S3 C–J). These results indicate that the detrimental effect
of increased dosage of DEFA1/DEFA3 genes on sepsis is not at-
tributable to a dysregulated inflammatory or antimicrobial response.
Excessive endothelial activation and dysfunction constitutes a
common host response to sepsis and is likely a key contributor to
the pathogenesis of sepsis (10–12). We asked whether endothe-
lial dysfunction played an important role in worse sepsis out-
comes of mice with HCN of DEFA1/DEFA3 genes. To address
this issue, we first used two-photon intravital confocal micros-
copy to study leukocyte adhesion in a single mesenteric vessel in
living mice at 72 h after CLP. Rhodamine 6G-labeled leukocytes
were captured by sequential videos and images (Fig. 2A and
Movies S1–S3), and they were quantified using time-lapse im-
aging. Adherent cells were defined as rhodamine 6G+ cells that
remained stationary along the inner surface of the vessel wall for
at least 1 min. Interestingly, the number of firmly adherent
leukocytes in mice carrying HCN of DEFA1/DEFA3 at 72 h post-
CLP was 285 ± 39/mm2, which was significantly higher than that
in mice with LCN ofDEFA1/DEFA3 and in WTmice (129 ± 27/mm2
and 34 ± 13/mm2, respectively) (Fig. 2B). In contrast, leuko-
cytes from the related sham-operated controls exhibited little
adherence to the microvasculature (SI Appendix, Fig. S4 A and B
and Movies S4–S6). In agreement with leukocyte adhesion find-
ings, a significant reduction in rolling velocity in the mesenteric
vessels of septic mice carrying HCN of DEFA1/DEFA3 was also
observed (Fig. 2C vs. SI Appendix, Fig. S4C). These findings
provide important in vivo evidence for aggregated leukocyte ad-
hesion and suggest a possible role of endothelial activation in the
progression of sepsis in mice carrying HCN of DEFA1/DEFA3.
Because endothelial activation is an early step in sepsis, we
explored if expression of endothelial adhesion molecules in vital
organs increased under the condition of sepsis. Immunohisto-
chemistry revealed a low degree of intercellular adhesion protein
1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1)
expression in lungs of WT mice and mice with LCN of DEFA1/
DEFA3, but a significantly increased expression of ICAM-1 and
VCAM-1 in lungs of mice carrying HCN of DEFA1/DEFA3, at
24 h after sepsis onset (SI Appendix, Fig. S5 A–D). We also in-
vestigated whether there were any changes in expression of
leukocyte adhesion molecules, and found that the expression
levels of lymphocyte function associated antigen-1 (LFA-1) and
very late antigen-4 (VLA-4) in peripheral blood leukocytes were
very low and not significantly different among the three genotype
groups (SI Appendix, Fig. S5 E and F).
Neutrophil-borne HNP-1 can synergize with platelets to stimulate
monocyte adhesion and enhance their recruitment, hence partici-
pating in acute and chronic inflammation (21). Combined with our
results, we tested whether the observed phenotype in transgenic mice
after sepsis challenge could be attributed to an altered monocyte
function. Thus, monocytes/macrophages were depleted 48 h before
CLP performance using clodronate liposomes. Notably, the depletion
of monocytes/macrophages did not impact the survival of mice car-
rying HCN of DEFA1/DEFA3 (SI Appendix, Fig. S6).
To further examine the contribution of endothelial activation
and dysfunction to the pathogenesis of sepsis in transgenic mice,
the effects of these genetic variations on vascular endothelial
integrity in vital organs/tissues, such as lungs, kidneys, and
mesenteric vessel beds were studied. Evans blue dye and FITC-
conjugated dextran leakage analyses are commonly used to as-
sess endothelial integrity and vascular permeability in vivo. In
both assays, compared with WT mice and the mice with LCN,
those carrying HCN of DEFA1/DEFA3 had significantly in-
creased extravasation of dyes in the vessel beds of lungs, kidneys,
and mesentery at 72 h after the initiation of sepsis (Fig. 3 A and
B and SI Appendix, Fig. S7 A and B). Taken together, these data
show that endothelial barrier dysfunction contributes to sepsis
deterioration in mice carrying HCN of DEFA1/DEFA3 genes.
Taken together, these findings demonstrate that after sepsis
onset, vascular endothelia are excessively activated and dys-
functional in mice carrying HCN of DEFA1/DEFA3.
Increased DEFA1/DEFA3 Gene Dose Results in Endothelial Cell
Pyroptosis During Sepsis. To characterize how endothelial bar-
rier function was affected in mice with HCN of DEFA1/DEFA3,
we then examined whether the endothelial cells were directly
damaged during septic challenge. CD31 is a surface marker
expressed by endothelial cells (32). Using immunofluorescence
analysis, we found that the sham-operated mice from the three
studied groups preserved intact endothelial cells in pulmonary,
renal, and mesenteric microvessels. Notably, at 72 h after sepsis
development, the mice carrying HCN of DEFA1/DEFA3 showed
a marked loss of CD31+ endothelial cells in microvessels from
lung (Fig. 3 C and D), kidney (Fig. 3 E and F), and mesentery (SI
Appendix, Fig. S7 C and D), which presumably resulted from
lethal injury of the endothelial cells.
Endothelial cell loss resulting from cell death has been ob-
served during severe infections and inflammation and been
demonstrated to contribute to vascular permeability (10). We
next examined whether endothelial cell death was responsible for
more severe endothelial barrier dysfunction in septic mice car-
rying the DEFA1/DEFA3 HCN variant. Single-cell suspension
that includes endothelial cells was generated from mouse lung
and analyzed using flow cytometry. Both in transgenic mice and
in WT mice, only a small proportion of CD31+ endothelial cells
exhibited apoptotic characteristics at 48 h after sepsis induction
(SI Appendix, Fig. S8A). In addition, the endothelial cells from
the three grouped mice showed no significant difference in ap-
optosis (Fig. 3G). We therefore explored whether these cells
underwent pyroptosis, a type of inflammatory cell death that has
recently been found to contribute endothelial barrier dysfunction
in infectious and inflammatory diseases (33, 34). Strikingly, a
higher proportion of CD31+ endothelial cells showed pyroptotic
death [stained with propidium iodide (PI) and fluorescent-labeled
inhibitors of caspase-1 (FLICA)–caspase-1, a key player in pyrop-
tosis (35)] at 48 h after sepsis onset (SI Appendix, Fig. S8B).
Moreover, this phenomenon was particularly pronounced in mice
carrying HCN of DEFA1/DEFA3 (Fig. 3H). Thus, these data pro-
vide evidence of enhanced endothelial cell pyroptosis in sepsis
pathogenesis in mice carrying the DEFA1/DEFA3 risk variant.
HNP-1 Promotes Endothelial Cell Pyroptosis. To determine how the
increased dose of DEFA1/DEFA3 led to endothelial cell pyrop-
tosis during sepsis, we first examined the protein level of HNP1–
3 in vivo after septic challenge. Immunohistochemical analysis of
lung tissues from WT and transgenic mice revealed markedly
elevated levels of HNP1–3 in mice carrying HCN of DEFA1/
DEFA3 at 24 and 48 h after CLP (SI Appendix, Fig. S9). Con-
sequently, we focused our further investigations on the impact of
HNP1–3 on endothelial cell viability. We assessed the direct effect
of HNP-1 on endothelial cell pyroptosis in vitro using a mouse
lung microvascular endothelial cell (MLMEC) line. Interestingly,
we found that a higher concentration of HNP-1 could activate
more cleaved caspase-1 in primed MLMECs (Fig. 4A). In addi-
tion, a higher concentration of HNP-1 promoted more cell death,
as reflected by lactate dehydrogenase (LDH) release (Fig. 4B).
However, two other important mediators of pyroptosis, non-
canonical caspase-11 inflammasome and gasdermin D (36, 37),
were not activated (SI Appendix, Fig. S10 A and B). Cleaved
caspase-3 was also not detected (SI Appendix, Fig. S10C). These
dose-dependent effects of HNP-1 on endothelial cell viability were
closely consistent with in vivo findings showing that mice carrying
HCN of DEFA1/DEFA3 had more pyroptotic endothelial cells
than those with LCN of DEFA1/DEFA3 and WT controls during
sepsis development.
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HNP1–3 has been reported to play multifunctional roles in
the immune system, but the specific receptors related to these
activities have not yet been well characterized. Our previous
study identified HNP-1 through direct binding to the purinergic
receptor P2X ligand-gated ion channel 7 (P2X7), promoting
LPS-primed macrophage pyroptosis (38). We therefore exam-
ined whether this receptor is responsible for HNP1–3-induced
pyroptosis in endothelial cells. Both in vivo and in vitro studies
showed that the expression levels of P2X7 in endothelial cells
were markedly increased under septic and inflammatory con-
ditions (SI Appendix, Figs. S11 and S12), suggesting a potential
function of P2X7. Furthermore, knockdown of P2X7 in
primed MLMECs using small interference RNA dramatically
reduced HNP-1–promoted cleaved caspase-1 levels as well as
released LDH levels (Fig. 4 C and D). These results show
that HNP-1 activates caspase-1 inflammasome to induce
pyroptotic death in primed endothelial cells via interaction
with P2X7.
Fig. 3. Increased gene copy number of DEFA1/DEFA3 leads to endothelial barrier dysfunction and endothelial cell pyroptosis after sepsis. (A) In vivo Evans
blue dye permeability assay in lungs (Left) and kidneys (Right) at 72 h after performance of CLP or sham operation in WT mice (n = 6 for CLP, and n = 5 for
sham), mice with LCN of DEFA1/DEFA3 (n = 6 for CLP, and n = 5 for sham), and mice with HCN of DEFA1/DEFA3 (n = 5 for each CLP and sham group). ***P <
0.001, two-way ANOVA with Bonferroni posttests. (B) In vivo FITC-dextran permeability assay in lungs (Left) and kidneys (Right) at 72 h after performance of
CLP or sham operation in WT mice (n = 11 for CLP, and n = 14 for sham), mice with LCN of DEFA1/DEFA3 (n = 13 for CLP, and n = 12 for sham), and mice with
HCN of DEFA1/DEFA3 (n = 16 for CLP, and n = 11 for sham). ***P < 0.001, two-way ANOVA with Bonferroni posttests. (C–F) Representative images and
comparisons of CD31+ endothelial cells in the lung (C and D) and renal glomeruli (E and F) at 72 h after performance of CLP or sham operation in WT mice
(n = 6 for CLP, and n = 5 for sham), mice with LCN of DEFA1/DEFA3 (n = 6 for CLP, and n = 5 for sham), and mice with HCN of DEFA1/DEFA3 (n = 6 for CLP, and
n = 5 for sham). The white arrowheads in E indicate renal glomeruli. CD31+ endothelial cells were quantified by the fluorescence intensity in at least five
different high-power fields from each slide. Red indicates CD31 staining; blue indicates DAPI staining. (Scale bars, 50 μm.) In D, *P = 0.040, **P = 0.003, two-way
ANOVA with Bonferroni posttests. In F, *P = 0.034, **P = 0.007, two-way ANOVA with Bonferroni posttests. (G) Quantification of apoptotic endothelial cells in
the lung at 48 h after performance of CLP or sham operation inWTmice (n = 3 for each CLP and sham group), mice with LCN ofDEFA1/DEFA3 (n = 3 for each CLP
and sham group), and mice with HCN of DEFA1/DEFA3 (n = 3 for each CLP and sham group) using flow cytometry. See also SI Appendix, Fig. S8A for flow
cytometry gating strategy. (H) Quantification of pyroptotic endothelial cells in the lung at 48 h after performance of CLP or sham operation in WT mice
(n = 5 for CLP, and n = 4 for sham), mice with LCN of DEFA1/DEFA3 (n = 5 for CLP, and n = 4 for sham), and mice with HCN of DEFA1/DEFA3 (n = 5 for CLP, and
n = 4 for sham) using flow cytometry. See also SI Appendix, Fig. S8B for flow cytometry gating strategy. ***P < 0.001, two-way ANOVAwith Bonferroni posttests.
In A, B, D, and F–H, data are presented as dot plots with horizontal bars representing means ± SEM.
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To further examine whether such a mechanism contributes to
the deleterious effect of increased dose of DEFA1/DEFA3 on
sepsis, BM-chimeric mice were generated by reconstituting le-
thally irradiated P2X7-deficient mice with BM from HCN of
DEFA1/DEFA3, LCN of DEFA1/DEFA3, or WT mice. As
expected, no significant difference in the survival rate was ob-
served among the chimeric P2X7-deficient mice during the 7-d
period after sepsis initiation (Fig. 4E). Because the Nod-like
receptor family pyrin domain containing 3 (NLRP3) is charac-
terized primarily as a canonical caspase-1–activating inflamma-
some downstream of P2X7 during pyroptosis (38–40), we also
confirmed the role of NLRP3 inflammasome in the observed
effect using BM-chimeric mice. The Nlrp3-deficient mice
reconstituted with BM from HCN of DEFA1/DEFA3, LCN of
DEFA1/DEFA3, or WT mice showed no significant difference in
survival rate after sepsis onset (Fig. 4F). However, when chimeric
caspase-11–deficient mice transplanted with BM from HCN of
DEFA1/DEFA3, LCN of DEFA1/DEFA3, or WT mice were
challenged with CLP, significantly higher mortality was observed
in those transplanted with BM from mice with HCN of DEFA1/
DEFA3 (Fig. 4G). This in vivo observation is consistent with the
in vitro findings showing that HNP-1 induces endothelial cell
pyroptosis in a caspase-11–independent manner. Collectively,
these data demonstrate that increased DEFA1/DEFA3 gene
dose, by producing elevated levels of HNP1–3, promotes endo-
thelial cell pyroptosis and vascular leakage, which is dependent
on P2X7-mediated canonical NLRP3/caspase-1 inflammasome
activation.
Blocking the Interaction of HNP1–3 and P2X7 Rescues Mice Carrying
the DEFA1/DEFA3 Risk Variant from Lethal Sepsis. Based on these
data, we reasoned that impeding the interaction between HNP1–
3 and P2X7 might inactivate downstream signaling and protect
the viability of endothelial cells. We therefore developed an
antibody to block HNP1–3 recognition by P2X7 receptor. To this
end, we used homologous modeling, molecular docking, and
molecular dynamics (MD) simulation techniques to predict a
likely heteromeric complex structure of HNP-1 bound to human
P2X7 (hP2X7) or mouse P2X7 (mP2X7). The disallowed regions
in the Ramachandran plots for both the modeled hP2X7 and
mP2X7 were lower than 1% (hP2X7, 0.7%; mP2X7, 0.4%) (SI
Appendix, Fig. S13 A and B), suggesting that the modeled
structures were acceptable for further protein–protein docking
calculations. For the HNP-1/hP2X7 or HNP-1/mP2X7 complex,
a total of 3,600 structures were generated by the ZDOCK web
server (41). The top 10 ranked binding structures for HNP-1/
hP2X7 or HNP-1/mP2X7 showed high similarity (SI Appendix,
Fig. S13 C and D). Therefore, the most stable structures gen-
erated by ZDOCK were used for the MD simulations. To
monitor the stability of the simulated systems, the RMSDs of the
Cα atoms from their initial position were analyzed. The RMSD
values of hP2X7 and mP2X7 tended to converge after 30–45 ns
of MD simulations (SI Appendix, Fig. S13 E and F). In addition,
Fig. 4. HNP-1 induces endothelial cell pyroptosis through P2X7-mediating canonical caspase-1 activation. (A) Representative Western blot analysis of
caspase-1 precursor (Pro-CASP1) and mature caspase-1 (p10) following stimulation with different concentrations of HNP-1 (0 μg/mL, 5 μg/mL, 15 μg/mL,
25 μg/mL) in MLMECs that were already primed with LPS (1 μg/mL) and IFN-γ (100 ng/mL). One representative of four independent experiments is shown.
α-Tubulin served as a loading control. See also SI Appendix, Fig. S16 for uncropped images of immunoblots. (B) Cell toxicity (measured by LDH release into the
medium) in response to different concentrations of HNP-1–stimulated MLMECs that were already primed with LPS and IFN-γ (n = 4). ***P < 0.001, one-way
ANOVA with Bonferroni posttests. (C) Representative Western blot analysis of Pro-CASP1 and p10 caspase-1 following HNP-1 (25 μg/mL) stimulation in
P2X7 siRNA and control siRNA-transfected MLMECs that were already primed with LPS and IFN-γ. One representative of four independent experiments is
shown. α-Tubulin served as a loading control. See also SI Appendix, Fig. S16 for uncropped images of immunoblots. (D) Cell toxicity (measured by LDH release
into the medium) following HNP-1 (25 μg/mL) stimulation in P2X7 siRNA and control siRNA-transfected MLMECs that were already primed with LPS and IFN-γ
(n = 4). **P = 0.004, one-way ANOVA with Bonferroni posttests. (E–G) Survival over time of lethally irradiated P2x7−/−mice (E), NLRP3−/−mice (F), and caspase-
11−/− mice (G) that were reconstituted with BM from WT mice, mice with LCN of DEFA1/DEFA3, and mice with HCN of DEFA1/DEFA3 and that were sub-
sequently subjected to CLP. In E, n = 6 for mice reconstituted with BM from WT mice, n = 8 for mice reconstituted with BM from mice carrying LCN of DEFA1/
DEFA3, and n = 7 for mice reconstituted with BM from mice carrying HCN of DEFA1/DEFA3. In F, n = 8 for mice reconstituted with BM fromWT mice, n = 9 for
mice reconstituted with BM from mice carrying LCN of DEFA1/DEFA3, and n = 11 for mice reconstituted with BM from mice carrying HCN of DEFA1/DEFA3. In
G, n = 13 for mice reconstituted with BM from WT mice, n = 12 for mice reconstituted with BM from mice carrying LCN of DEFA1/DEFA3, and n = 9 for mice
reconstituted with BM from mice carrying HCN of DEFA1/DEFA3. **P = 0.009, ***P < 0.001, log-rank test. In B and D, data are presented as dot plots with
horizontal bars representing means ± SEM.
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the RMSD values of HNP-1 in both the HNP-1/hP2X7 and
HNP-1/mP2X7 complexes were quite stable during the simula-
tions. Subsequently, the trajectories of the last 20-ns simulations
were taken for the following energetic analysis. To illuminate the
roles of individual residues in determining the interactions be-
tween HNP-1 and hP2X7 or mP2X7, the molecular mechanics/
generalized born surface area (MM/GBSA) binding free energy
was decomposed into the contributions of each residue. The
results showed that the CYCRIPA and IYQGRLW motifs in
HNP-1 formed favorable interactions with hP2X7 or mP2X7
(Fig. 5 A and B). In particular, the CYCRIPA motif may
maintain the open state to allow for the transportation of ions in
both HNP-1/hP2X7 and HNP-1/mP2X7 complexes (Fig. 5 C and
D and SI Appendix, Fig. S13 G and H). Thus, the CYCRIPA
motif was selected as an antigen to develop antibodies with the
potential to inhibit the interaction between HNP-1 and P2X7.
Accordingly, we generated a set of monoclonal antibodies and
screened them for their ability to bind HNP-1. Finally, two
monoclonal antibodies (designated B6B4 and A4B11) were se-
lected because of their cross-reactivity with HNP-1 [dissociation
constant (KD) value of 40.2 nM for B6B4 and 13.8 nM for
A4B11]. The antibodies were then tested to assess their ability
to block HNP-1 binding to P2X7 on primed MLMECs. Pre-
incubation of HNP-1 with the B6B4 antibody more significantly
alleviated endothelial cell pyroptosis, as manifested by a mark-
edly reduced level of activated caspase-1 and released LDH in
primed MLMECs (Fig. 5 E and F), suggesting a potent in-
terference with the HNP-1/P2X7 interaction.
We next investigated the bioactivity of the blocking activity of
B6B4 in vivo. We subjected mice carrying the HCN of DEFA1/
DEFA3 genes to the CLP model and treated them three times
with the blocking antibody (300 μg, by tail vein injection; im-
mediately, 24 and 48 h after performance of sepsis), or admin-
istered an equal amount of mouse IgG or an equal volume of
normal saline (Fig. 6A). Notably, treatment with B6B4 antibody
had a significant protective effect on septic mice carrying HCN
of DEFA1/DEFA3 genes, as evidenced by a reduced 7-d mor-
tality (Fig. 6B). Additionally, mice treated with the B6B4 anti-
body generally appeared healthy, whereas those treated with IgG
or normal saline were inactive and looked ill at 24 h after CLP
(Movie S7). However, treatment with B6B4 antibody did not
confer any protective effect on septic mice with LCN of DEFA1/
DEFA3 genes or with the WT genotype (SI Appendix, Fig. S14).
To examine the therapeutic potential of the blocking antibody in
established sepsis, we treated mice with HCN of DEFA1/DEFA3
at an initial time of 12 h post-CLP and thereafter at 36 and 60 h
Fig. 5. Monoclonal antibodies block the interaction between HNP-1 and P2X7 in vitro. (A and B) Per residue contributors to the binding free energy of HNP-
1 with hP2X7 (A) or mP2X7 (B). (C and D) Structure analysis of the last snapshot of the HNP-1/hP2X7 complex (C) and HNP-1/mP2X7 complex (D) from MD
simulations. The molecular surface views are presented. The three monomers of hP2X7 or mP2X7 are colored in gray. The CYCRIPA motif, IYQGRLWmotif and
other motifs of HNP-1 are colored in red, blue, and yellow, respectively. (E) Representative Western blot analysis of Pro-CASP1 and p10 caspase-1 following
HNP-1 (25 μg/mL) combined with monoclonal antibody (B6B4 or A4B11) or control IgG treatment in MLMECs that were already primed by LPS (1 μg/mL) and
IFN-γ (100 ng/mL). One representative of four independent experiments is shown. α-Tubulin served as a loading control. See also SI Appendix, Fig. S16 for
uncropped images of immunoblots. (F) Cell toxicity (measured by LDH release into the medium) in HNP-1 combined with monoclonal antibody (B6B4 or
A4B11) or control IgG-treated MLMECs that were already primed with LPS and IFN-γ (n = 4). Data are presented as dot plots with horizontal bars representing
means ± SEM. *P = 0.028, ***P < 0.001, one-way ANOVA with Bonferroni posttests.
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(Fig. 6C). Strikingly, this treatment regimen more effectively
protected mice with HCN of DEFA1/DEFA3 from mortality
(Fig. 6D). Immunofluorescent analysis showed substantially in-
creased CD31+ endothelial cells in the lungs (Fig. 6 E and F) and
kidneys (Fig. 6 G and H), as well as in mesenteric vessels (SI Ap-
pendix, Fig. S15), in B6B4 antibody-treated mice at 72 h after CLP,
compared with IgG-treated controls. Thus, the blocking antibody
against the interaction between HNP-1 and P2X7 can protect mice
with HCN of DEFA1/DEFA3 from lethal sepsis.
Discussion
CNVs are the most common mechanism of structural genetic
diversity and play a key role in human health and common dis-
eases (42, 43). Although there is abundant evidence of beneficial
duplications, particularly in the context of stressful or perturbed
environmental conditions, increases in gene copy number are
usually implicated in increased susceptibility to a wide range of
human diseases (44). However, little is known about how rare
CNVs contribute to the risk of the diseases and the complex
phenotypes. Animal model experiments are the mainstay of
distinguishing causality from association in human genetics. The
use of transgenic mouse models allows for the study of direct
effects of different gene dosages on specific phenotypes at the
pathophysiological, cellular, and molecular levels (45, 46). In the
present study, mice engineered to have HCN of DEFA1/DEFA3
genes showed more severe organ damage and a worse outcome
after sepsis challenge, indicating a genotype-restricted function in
phenotype development. Thus, combined with our previous case-
control genetic association study, these human and transgenic
mouse model-based findings indicate that HCN of DEFA1/
DEFA3 is a causative genetic factor for sepsis development.
Defensins contribute to innate immunity through diverse ac-
tions. Neutrophil-derived α-defensins are able to affect profound
changes in the inflammatory environment while also serving as
effective antimicrobial peptides. HNP-1 functions as a molecular
brake on macrophage-driven inflammation by preventing protein
translation (22). However, no pathophysiological differences
related to these biological activities of HNP1–3 were detected
between HCN and LCN of DEFA1/DEFA3 mice during sepsis
development. Interestingly, a recent study by London et al. (13)
also found that activating an endothelium-specific, Robo4-
dependent signaling pathway with the soluble ligand Slit could
strengthen the vascular barrier, reduce vascular permeability in
the lung and other organs, and increase survival in different
murine models of sepsis, but did not alter plasma concentrations
of a panel of cytokines and chemokines. These findings indicate
that the marked and abrupt cytokine storm during sepsis is
mainly generated by the innate immune response triggered by
microbial infection or initial insult. We surmise that vascular
endothelial dysfunction can result in severe tissue/organ damage
and fatal outcome, without further amplifying the inflammatory
response during sepsis. Thus, the breakdown in endothelial
barrier function plays a crucial role in the pathogenesis of sepsis,
and buttressing the endothelial barrier may be sufficient to re-
duce mortality from sepsis.
Emerging evidence suggests that endothelial activation in vital
organ vasculatures is an early and key step in the pathogenesis of
sepsis. Endothelial cell activation is marked by the expression of
endothelial cell-surface adhesion molecules, such as VCAM-1,
and ICAM-1 (47). In the present study, significantly elevated
expression levels of VCAM-1 and ICAM-1 were observed in the
lung tissue of mice carrying HCN of DEFA1/DEFA3 at 24 h after
sepsis onset compared with those of mice with LCN of DEFA1/
DEFA3 and WT mice. These findings indicate a more activated
state of vascular endothelial cells in vital organs of mice carrying
HCN of DEFA1/DEFA3 after sepsis challenge. Excessive endo-
thelial activation can lead to endothelial dysfunction with the
expression as endothelial cell death. On the other hand, neu-
trophil HNP-1 can stimulate monocyte adhesion and enhance
their recruitment to participate in acute and chronic inflamma-
tion (21). However, depletion of macrophage/monocytes did
not confer any protection against lethal sepsis for mice carrying
HCN of DEFA1/DEFA3. Thus, mechanisms such as endothelial
Fig. 6. The blocking antibody B6B4 rescues mice with HCN of DEFA1/DEFA3
from sepsis. (A and B) Mice were subjected to CLP, and B6B4 (300 μg per
mouse), mouse IgG (300 μg per mouse), or normal saline (NS; equal volume)
were intravenously administered at 0, 24, and 48 h after CLP (A). Survival
over time of mice with HCN of DEFA1/DEFA3 was assessed (B). *P =
0.011 between NS-treated group and B6B4-treated group, *P = 0.016 be-
tween IgG-treated group and B6B4-treated group, log-rank test. (C and D)
Mice were subjected to CLP, and B6B4 (300 μg per mouse), mouse IgG (300
μg per mouse), or normal saline (NS; equal volume) were intravenously ad-
ministered at 12, 36, and 60 h after CLP (C). Survival over time of mice with
HCN of DEFA1/DEFA3 was assessed (D). *P = 0.031, ***P < 0.001, log-rank
test. (E–H) Representative images and comparisons of CD31+ endothelial
cells in the lung (E and F) and renal glomeruli (G and H) from mice with HCN
of DEFA1/DEFA3 that were subjected to CLP and treated with mouse IgG
(n = 3) or B6B4 (n = 3) as shown in C, and the mice were killed at 72 h after
CLP. Red indicates CD31+ staining; blue indicates DAPI staining. (Scale bars,
50 μm.) In B, n = 17 for mice with NS treatment, n = 17 for mice with IgG
treatment, and n = 20 for mice with B6B4 treatment. In D, n = 6 for mice
with NS treatment, n = 6 for mice with IgG treatment, and n = 8 for mice
with B6B4 treatment. In F and H, data are presented as dot plots with hor-
izontal bars representing means ± SEM. In F, *P = 0.011, two-tailed unpaired
t test. In H, *P = 0.032, two-tailed unpaired t test.
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cell death are favored to contribute to the endothelial barrier dys-
function in septic mice carrying HCN of DEFA1/DEFA3.
Our in vivo results strongly suggest a connection between the
DEFA1/DEFA3 risk variant and the breakdown of endothelial
barrier function. Endothelial barrier dysfunction is a central
pathogenic feature of sepsis. There is increasing evidence that
widespread endothelial cell death, especially pyroptotic cell
death, is an initial mechanism mediating endothelial injury under
inflammatory and infectious conditions. For example, caspase-
11–mediated endothelial pyroptosis is requisite for endotoxemia-
induced lung injury (33), while endothelial cell pyroptosis via
caspase-1–dependent inflammasome activation leads to endo-
thelial dysfunction in hyperhomocysteinemia-related vascular
inflammation and atherosclerosis (34). In the current study,
caspase-1–dependent, but not caspase-11–mediated, endothelial
pyroptosis was found both in LPS-primed endothelial cells stimu-
lated by HNP-1 and in the DEFA1/DEFA3 risk-variant transgenic
mice after sepsis progression, where HNP-1–dependent damage
was triggered through signaling by P2X7 receptor. In agreement
with these findings, the BM chimera experiments further affirmed
a central role for nonhematopoietic P2X7 and its downstream
inflammasome components NLRP3 and caspase-1 in the patho-
genic changes. These data highlight the importance of endothelial
cell survival and endothelial barrier function during sepsis challenge
in DEFA1/DEFA3 risk-variant transgenic mice.
Importantly, mechanistic insights into the interaction between
HNP-1 and P2X7 raised the possibility of new therapeutic mo-
dalities that we could test in septic mice carrying the DEFA1/
DEFA3 risk variant. Based on the structural model developed in
the present study, we generated a blocking antibody to impede
the binding of HNP1–3 to P2X7. Treatment with this monoclo-
nal antibody in the DEFA1/DEFA3 risk-variant transgenic mice,
but not in the mice with other genotypes, indeed dramatically
improved endothelial barrier function and protected mice from
sublethal sepsis, suggesting a precision medicine approach to en-
able targeted therapeutic intervention to improve sepsis outcomes.
Currently, progress in sepsis research is severely hampered by
a heterogeneous disease phenotype. This heterogeneity mani-
fests as a diversity of host responses that occur in different pa-
tients, making therapeutic management challenging (48, 49).
Effective targeted therapy for sepsis requires an understanding
of the heterogeneity of the individual host response (50). A
precise approach using biomarkers allows for the identification
of subgroups of patients with different host responses and spe-
cific individuals who are likely to benefit from a personalized
therapy (51–53). Our genetic approach may classify individuals
into subpopulations that differ in their susceptibility to sepsis, in
the pathophysiology of sepsis, and in their response to a specific
treatment according to their genomic information. Thus, our
study not only provides insights into the pathogenesis of sepsis
but also suggests a conceptual framework for the treatment of
sepsis through a tailored approach.
Materials and Methods
Generation of Transgenic Mice. Transgenic mice carrying HNP1–3-encoding
genes DEFA1/DEFA3 were generated using the P1 artificial chromosome
construct (clone P1 34) (54). The transgenic construct was verified by se-
quencing and introduced into C57BL/6 mice. Transgene integration was
identified by genomic PCR and high-throughput sequencing analysis. Mouse
experiments were carried out in compliance with relevant animal-use
guidelines and ethical regulations, and protocols for mouse experiments
were approved by the institutional review boards of Zhejiang University
School of Medicine, Hangzhou, China.
Characterization of Transgenic Mice. The genomic copy number of DEFA1/
DEFA3 was genotyped by means of quantitative real-time PCR, as described
previously (27). The expression of the protein was determined in myeloid
marrow precursors and peripheral blood polymorphonuclear cells, as well as
in perfused lung, liver, and kidney by an immunostaining or immunoblot-
ting test, as previously described (55).
CLP-Induced Sepsis Model and Treatment Regimen. Eight- to 10-wk-old
transgenic mice or WT mice were subjected to CLP, as previously described
(31). Mortality was assessed every 6–8 h. See SI Appendix for more details.
In some experiments for sepsis treatment, 300 μg of the B6B4 antibody
was consecutively intravenously administered to mice via the tail vein im-
mediately or at 12 h after CLP performance and then at 24 and 48 h after the
first administration. As a control, equal amounts of normal saline or mouse
IgG (I5381; Sigma-Aldrich) were administered in the same manner.
Generation of BM Chimeric Mice. To generate BM-chimeric mice, 8- to 10-wk-
old recipient mice were lethally irradiated (8 Gy) using the RS 2000 X-ray
Biological Irradiator (Rad Source Technologies) and reconstituted with
three million bone marrow cells from donors by intravenous injection. Pro-
phylactic antibiotics were administered during 1 wk before and the initial
2 wk after transplantation. Chimeras were used for further experiments 6–
8 wk after the initial reconstitution.
Histopathology. For histopathology analysis, the lung, liver, and kidney tissues
were fixed in a 4% paraformaldehyde-buffered solution for 24 h, embedded
in paraffin and cut into 4-μm-thick sections, followed by H&E staining. For
details, see SI Appendix.
In Vivo Two-Photon Laser-Scanning Microscopy Imaging. The dynamic changes
in microvascular blood flow and leukocyte adhesion were captured by two-
photon laser-scanning microscopy imaging in vivo (56). After they were
anesthetized, the mice were placed on a heated stage and their core tem-
perature was measured and maintained at 37 °C. A 1-cm incision was then
made in the abdomen, and the mesentery was carefully externalized with a
swab. The mesentery was covered with 1.5% (wt/vol) low-melting-point
agarose saline, and glass (Φ = 6 mm) was placed horizontally on the aga-
rose. In vivo imaging was performed using an upright Olympus two-photon
laser scanning confocal microscope (BX61W1-FV1000; Olympus) with an
excitation source of a Spectra-Physics MaiTai HP Deep See femtosecond Ti:Sa
laser. The wavelength of the laser was set at 800 nm. A long-working dis-
tance (2 mm) water-immersion objective (25×, NA = 1.05) was adopted for in
vivo bioimaging. For studies of leukocyte adhesion, leukocytes were labeled
in vivo with an intravenous bolus injection of 100 μL of a 0.02% solution of
rhodamine 6G (Sigma-Aldrich). The images were taken at scanning speed of
2 μs per pixel with a resolution of 1,024 × 1,024 pixels and 50 pictures in
total. In vivo leukocyte adhesion and rolling velocity was measured manually
using ImageJ (NIH) and Imaris (Olympus) software.
In Vivo Permeability Assay. The changes in vascular permeability were
assessed with Evans blue dye and FITC-dextran leakage from the blood into
tissues in vivo. For details, see SI Appendix.
Flow Cytometry Analysis of Cell Pyroptosis. For pyroptosis analysis, the single-
cell suspension from mouse lung tissue was incubated with allophycocyanin-
conjugated anti-CD31 antibody (551262; BD Biosciences) for 30 min. After
washing, the cells were incubated with carboxyfluorescein FLICA (Immuno-
Chemistry Technologies), which binds to activated caspase-1, and PI, as de-
scribed in the manufacturer’s instructions. The cells were then analyzed by
flow cytometry. Acquisition was performed on 30,000 events using a BD LSR
Fortessa (BD Biosciences), and the data were analyzed by BD FACSDiva (BD
Biosciences). The percentage of both FLICA and PI double-stained events in
CD31+ cells was taken as the percentage of pyroptotic endothelial cells.
Modeling the Interaction Between HNP-1 and P2X7. The sequences of hP2X7
(GenBank accession no. CAA73360.1) and mP2X7 (GenBank accession no.
CAA08853.1) were obtained from the GenBank database. The 3D structures
of hP2X7 and mP2X7 were built from the X-ray structure of the human
P2X3 using the SWISS-MODEL web server (57). The crystal structure of the
human HNP-1 was retrieved from the Protein Data Bank (PDB ID code
3GNY). The binding structure of HNP-1 in complex with hP2X7 or mP2X7 was
predicted using the ZDOCK protein–protein docking web server (41). The
most stable structures of HNP-1/hP2X7 and HNP-1/mP2X7 generated by
ZDOCK were preoriented coordinates with respect to the normal membrane
(z axis) from the orientations of proteins in the membranes database (58).
Each of the oriented systems was inserted into a preequilibrated 1,2-dioleoyl-
sn-glycero-3-phosphocholine bilayer surrounded by a 150-mM KCl aqueous salt
solution using the Membrane Builder module in the CHARMM-GUI web server
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(59). The molecular mechanics parameters from the ff12SB force field,
lipid14 force field, and Joung/Cheatham ion parameters for TIP3P water
(ionsjc_tip3p) were assigned to the proteins, lipids, and ions, respectively,
using the LEaP module of AMBER 16. The initial system sizes were ∼119 ×
119 × 165 Å with more than 260,000 atoms.
MD simulations were carried out by using the pmemd.cuda module in
AMBER 16. A prior multistage molecular mechanics minimization was uti-
lized to remove unfavorable contacts. Afterward, each system was heated to
300 K over a period of 400 ps and equilibrated over 4 ns in the NPT ensemble
(T = 300 K and P = 1 bar). Finally, each system was submitted to 90 ns NPT
(T = 300 K and P = 1 bar) MD simulations. The binding free energy (ΔGbind)
between HNP-1 and hP2X7 or mP2X7 was calculated by the MM/GBSA ap-
proach based on 200 snapshots that were evenly extracted from the last
20-ns MD trajectories, as described previously (60, 61).
Statistical Analysis. Data are presented as mean ± SEM unless indicated
otherwise. Comparisons between two groups were performed by unpaired
two-tailed t test. Comparisons between more than two groups were per-
formed by one-way ANOVA with Bonferroni posttests, whereas comparisons
with two or more independent variable factors were performed by two-way
ANOVA followed by Bonferroni posttests. Survival data were analyzed with
the log-rank test. Data were analyzed and plotted in Prism 7.0 software
(GraphPad). P < 0.05 was considered statistically significant.
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